West Pharmaceutical Services Management
Management criteria checks 4/4
West Pharmaceutical Services' CEO is Eric Green, appointed in Apr 2015, has a tenure of 11.08 years. total yearly compensation is $7.19M, comprised of 16.4% salary and 83.6% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $56.79M. The average tenure of the management team and the board of directors is 2.3 years and 10.3 years respectively.
Key information
Eric Green
Chief executive officer
US$7.2m
Total compensation
| CEO salary percentage | 16.37% |
| CEO tenure | 11.1yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.3yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
Seeking Alpha • Apr 30
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind
Summary West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength. I rate WST a long-term 'hold' due to exemplary dividend safety and a fortress balance sheet, but the current valuation is only slightly below fair value. Read the full article on Seeking Alpha
Narrative Update • Apr 27
WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power
Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.Narrative Update • Feb 07
WST: Margin Resilience And Drug Delivery Portfolio Shift Will Support Earnings Power
Analysts have trimmed their price target on West Pharmaceutical Services by about US$7. This reflects updated assumptions around slightly softer revenue growth, a modestly higher discount rate, a small adjustment to future P/E expectations, and a marginally stronger profit margin outlook.Narrative Update • Jan 24
WST: 2026 Drug Delivery Focus And New Syringe Platform Will Support Earnings Power
Analysts have kept their fair value estimate for West Pharmaceutical Services steady at about $345.71 per share, with only slight tweaks to assumptions like the discount rate, long term revenue growth, profit margin, and future P/E, which together feed into their updated price target narrative. What's in the News West Pharmaceutical Services agreed to sell all manufacturing and supply rights for its SmartDose 3.5 mL On Body Delivery System, along with associated facilities, to AbbVie for total consideration of US$112.5 million at close, subject to working capital and other adjustments (Key Developments).Narrative Update • Jan 07
WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power
Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.Narrative Update • Dec 19
WST: Normalizing End Markets Will Support Stronger Earnings Base Into 2026
Analysts have modestly raised their price target on West Pharmaceutical Services to approximately $370, up from about $310. This reflects increased earnings estimates, a stronger setup into 2026, and improving, more stable end markets.Narrative Update • Dec 05
WST: Normalizing End Markets Will Support Strong Earnings Base Into 2026
Analysts have nudged their price target for West Pharmaceutical Services slightly higher to approximately $370, reflecting increased confidence in the company’s earnings power and growth drivers as market conditions normalize and set up favorably into 2026. Analyst Commentary Analyst views on West Pharmaceutical Services remain broadly constructive, with recent target hikes reflecting growing conviction that the company can sustain its earnings recovery as end markets normalize into 2026.Narrative Update • Nov 21
WST: Strong 2025 Outlook and Management Confidence Will Sustain Positive Momentum
West Pharmaceutical Services has seen its average analyst price target raised, with significant increases attributed to strong quarterly results, growing end market confidence, and a positive management outlook for 2026, according to analysts. Analyst Commentary Analysts have responded to West Pharmaceutical Services' recent performance and outlook with a range of observations tying directly to the company's valuation, execution, and growth prospects.Narrative Update • Nov 07
WST: Sustained Earnings Momentum Will Drive Confidence Into 2026
West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.Narrative Update • Oct 23
Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance
Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.Analysis Article • Jul 25
West Pharmaceutical Services, Inc.'s (NYSE:WST) Shares Climb 25% But Its Business Is Yet to Catch Up
West Pharmaceutical Services, Inc. ( NYSE:WST ) shareholders have had their patience rewarded with a 25% share price...Analysis Article • Jul 13
Here's Why West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Mar 11
West Pharmaceutical: Remains A Strong Long-Term Prospect
Summary West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy. Key risks include management's strategic decisions and valuation, but the worst seems behind, with attractive prices for long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
Summary The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
West Pharmaceuticals: Cannot Wrap My Head Around Valuations (Rating Downgrade)
Summary West Pharmaceutical Services stock is down 16% on deteriorating fundamentals. WST's business is contracting, with lower sales growth, compressed margins, and declining ROIC, making current valuations unjustifiable. Industry advantages exist, but high multiples and low incremental returns suggest limited compounding ability. I revise WST to hold with a $300-$330/share valuation, emphasizing the need for it to produce 4%+ sales growth and improved ROIC FY'26 to justify current prices. Read the full article on Seeking AlphaSeeking Alpha • Oct 11
West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Summary West Pharmaceutical Services' stock has been sluggish, trading near its 52-week low, with analysts downgrading estimates and technical indicators pointing to further downside. The company has a strong market position in injectable drug delivery systems, but post-COVID demand normalization and destocking have impacted recent performance. Despite robust seasonal trends, the stock is vulnerable to tax-loss selling, with Morgan Stanley naming it among the most at-risk stocks. Given these factors, a cautious hold on West Pharma is recommended, awaiting potential recovery in Q4 and beyond. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$543m |
| Dec 31 2025 | US$7m | US$1m | US$494m |
| Sep 30 2025 | n/a | n/a | US$492m |
| Jun 30 2025 | n/a | n/a | US$488m |
| Mar 31 2025 | n/a | n/a | US$467m |
| Dec 31 2024 | US$8m | US$1m | US$493m |
| Sep 30 2024 | n/a | n/a | US$500m |
| Jun 30 2024 | n/a | n/a | US$525m |
| Mar 31 2024 | n/a | n/a | US$569m |
| Dec 31 2023 | US$9m | US$1m | US$593m |
| Sep 30 2023 | n/a | n/a | US$559m |
| Jun 30 2023 | n/a | n/a | US$519m |
| Mar 31 2023 | n/a | n/a | US$552m |
| Dec 31 2022 | US$8m | US$1m | US$586m |
| Sep 30 2022 | n/a | n/a | US$631m |
| Jun 30 2022 | n/a | n/a | US$686m |
| Mar 31 2022 | n/a | n/a | US$684m |
| Dec 31 2021 | US$9m | US$1m | US$662m |
| Sep 30 2021 | n/a | n/a | US$613m |
| Jun 30 2021 | n/a | n/a | US$519m |
| Mar 31 2021 | n/a | n/a | US$423m |
| Dec 31 2020 | US$8m | US$989k | US$346m |
| Sep 30 2020 | n/a | n/a | US$312m |
| Jun 30 2020 | n/a | n/a | US$286m |
| Mar 31 2020 | n/a | n/a | US$261m |
| Dec 31 2019 | US$7m | US$936k | US$242m |
Compensation vs Market: Eric's total compensation ($USD7.19M) is below average for companies of similar size in the US market ($USD14.79M).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Green (55 yo)
11.1yrs
Tenure
US$7,190,876
Compensation
Mr. Eric M. Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.1yrs | US$7.19m | 0.25% $ 56.8m | |
| Senior VP & CFO | less than a year | US$11.80m | 0.0042% $ 943.4k | |
| Chief HR Officer & Senior VP | 10.6yrs | US$1.39m | 0.024% $ 5.3m | |
| SVP & Chief Proprietary Segment Officer | 1yr | US$2.40m | 0.00087% $ 194.5k | |
| VP of Finance & Chief Accounting Officer | 6yrs | no data | 0.0022% $ 482.9k | |
| Senior VP & CTO | less than a year | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP | less than a year | no data | no data | |
| Vice President of Global Communications | no data | no data | no data | |
| Senior Vice President of Strategy & Corporate Development | 2.5yrs | no data | 0.00079% $ 176.6k | |
| Senior VP and Chief Quality & Regulatory Officer | 4yrs | no data | no data | |
| President of Contract Manufacturing | 2.1yrs | no data | no data |
2.3yrs
Average Tenure
55yo
Average Age
Experienced Management: WST's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11yrs | US$7.19m | 0.25% $ 56.8m | |
| Independent Director | 12.3yrs | US$344.94k | 0.025% $ 5.5m | |
| Lead Independent Director | 6.3yrs | US$353.84k | 0.0067% $ 1.5m | |
| Independent Director | 18.6yrs | US$355.94k | 0.062% $ 13.8m | |
| Independent Director | 1.4yrs | US$330.94k | 0.0022% $ 500.7k | |
| Independent Director | 15.3yrs | US$344.94k | 0.062% $ 13.8m | |
| Independent Director | 15.3yrs | US$329.94k | 0.065% $ 14.5m | |
| Independent Director | 9.7yrs | US$332.14k | 0.016% $ 3.5m | |
| Independent Director | 3.8yrs | US$329.94k | 0.0039% $ 865.1k | |
| Independent Director | 14.3yrs | US$329.94k | 0.045% $ 10.0m | |
| Independent Director | 8.9yrs | US$334.94k | no data | |
| Independent Director | 4.8yrs | US$343.84k | 0.0051% $ 1.1m |
10.3yrs
Average Tenure
65yo
Average Age
Experienced Board: WST's board of directors are seasoned and experienced ( 10.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/26 14:19 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
West Pharmaceutical Services, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Lawrence Marsh | Barclays |
| Michael Ryskin | BofA Global Research |